BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37814565)

  • 21. Fecal Microbiota Transplantation for Refractory and Recurrent
    Bang BW; Park JS; Kim HK; Shin YW; Kwon KS; Kwon HY; Baek JH; Lee JS
    Korean J Gastroenterol; 2017 Apr; 69(4):226-231. PubMed ID: 28449424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study.
    Ianiro G; Bibbò S; Masucci L; Quaranta G; Porcari S; Settanni CR; Lopetuso LR; Fantoni M; Sanguinetti M; Gasbarrini A; Cammarota G
    Dig Liver Dis; 2020 Dec; 52(12):1390-1395. PubMed ID: 33004295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent
    Svensson CK; Cold F; Ribberholt I; Zangenberg M; Mirsepasi-Lauridsen HC; Petersen AM; Helms M
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-generational bacterial strain transfer to an infant after fecal microbiota transplantation to a pregnant patient: a case report.
    Wei S; Jespersen ML; Baunwall SMD; Myers PN; Smith EM; Dahlerup JF; Rasmussen S; Nielsen HB; Licht TR; Bahl MI; Hvas CL
    Microbiome; 2022 Nov; 10(1):193. PubMed ID: 36352460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.
    Lee CH; Chai J; Hammond K; Jeon SR; Patel Y; Goldeh C; Kim P
    Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1731-1735. PubMed ID: 31165961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial.
    Jiang ZD; Jenq RR; Ajami NJ; Petrosino JF; Alexander AA; Ke S; Iqbal T; DuPont AW; Muldrew K; Shi Y; Peterson C; Do KA; DuPont HL
    PLoS One; 2018; 13(11):e0205064. PubMed ID: 30388112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term beneficial effect of faecal microbiota transplantation on colonisation of multidrug-resistant bacteria and resistome abundance in patients with recurrent Clostridioides difficile infection.
    Nooij S; Vendrik KEW; Zwittink RD; Ducarmon QR; Keller JJ; Kuijper EJ; Terveer EM;
    Genome Med; 2024 Feb; 16(1):37. PubMed ID: 38419010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease.
    Hourigan SK; Chen LA; Grigoryan Z; Laroche G; Weidner M; Sears CL; Oliva-Hemker M
    Aliment Pharmacol Ther; 2015 Sep; 42(6):741-52. PubMed ID: 26198180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal Bile Acid Composition Changes Following Faecal Microbiota Transplantation for Clostridioides difficile Infection in Children With and Without Underlying Inflammatory Bowel Disease.
    Chen LA; Oliva-Hemker M; Radin A; Weidner M; O'Laughlin BD; Sears CL; Javitt NB; Hourigan SK
    J Crohns Colitis; 2023 Aug; 17(8):1364-1368. PubMed ID: 36988432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent
    Mullish BH; McDonald JAK; Pechlivanis A; Allegretti JR; Kao D; Barker GF; Kapila D; Petrof EO; Joyce SA; Gahan CGM; Glegola-Madejska I; Williams HRT; Holmes E; Clarke TB; Thursz MR; Marchesi JR
    Gut; 2019 Oct; 68(10):1791-1800. PubMed ID: 30816855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection.
    Perler BK; Chen B; Phelps E; Allegretti JR; Fischer M; Ganapini V; Krajiceck E; Kumar V; Marcus J; Nativ L; Kelly CR
    J Clin Gastroenterol; 2020 Sep; 54(8):701-706. PubMed ID: 32011405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Faecal microbiota transplantation as a home therapy to frail older people.
    Jørgensen SMD; Rubak TMM; Damsgaard EM; Dahlerup JF; Hvas CL
    Age Ageing; 2020 Oct; 49(6):1093-1096. PubMed ID: 32365381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis.
    Hui W; Li T; Liu W; Zhou C; Gao F
    PLoS One; 2019; 14(1):e0210016. PubMed ID: 30673716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.
    Jan N; Hays RA; Oakland DN; Kumar P; Ramakrishnan G; Behm BW; Petri WA; Marie C
    mSphere; 2021 Oct; 6(5):e0066921. PubMed ID: 34704776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions.
    Ianiro G; Masucci L; Quaranta G; Simonelli C; Lopetuso LR; Sanguinetti M; Gasbarrini A; Cammarota G
    Aliment Pharmacol Ther; 2018 Jul; 48(2):152-159. PubMed ID: 29851107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT).
    Allegretti JR; Kassam Z; Fischer M; Kelly C; Chan WW
    J Clin Gastroenterol; 2019 Oct; 53(9):e405-e408. PubMed ID: 30882536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile.
    Tixier EN; Verheyen E; Luo Y; Grinspan LT; Du CH; Ungaro RC; Walsh S; Grinspan AM
    Dig Dis Sci; 2022 Mar; 67(3):978-988. PubMed ID: 33748913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience.
    Cheng YW; Phelps E; Ganapini V; Khan N; Ouyang F; Xu H; Khanna S; Tariq R; Friedman-Moraco RJ; Woodworth MH; Dhere T; Kraft CS; Kao D; Smith J; Le L; El-Nachef N; Kaur N; Kowsika S; Ehrlich A; Smith M; Safdar N; Misch EA; Allegretti JR; Flynn A; Kassam Z; Sharfuddin A; Vuppalanchi R; Fischer M
    Am J Transplant; 2019 Feb; 19(2):501-511. PubMed ID: 30085388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.
    Mintz M; Khair S; Grewal S; LaComb JF; Park J; Channer B; Rajapakse R; Bucobo JC; Buscaglia JM; Monzur F; Chawla A; Yang J; Robertson CE; Frank DN; Li E
    PLoS One; 2018; 13(1):e0190997. PubMed ID: 29385143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Retrospective Comparison of Fecal Microbial Transplantation Methods for Recurrent Clostridium Difficile Infection.
    Cohen NA; Livovsky DM; Yaakobovitch S; Ben Yehoyada M; Ben Ami R; Adler A; Guzner-Gur H; Goldin E; Santo ME; Halpern Z; Paz K; Maharshak N
    Isr Med Assoc J; 2016 Oct; 18(10):594-599. PubMed ID: 28471618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.